Richard Pzena
Pzena Investment Management
Richard Pzena Medtronic PLC stake
total: 584
Pzena Investment Management MDT trades
- Total transactions:
- 17
- New positions:
- 2
- Sold out:
- 1
- Added:
- 9
- Reduced:
- 5
- Held since:
- 2023 Q1
- Held for:
- 14 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Richard Pzena holds 3,147,999 Medtronic PLC (MDT) shares with a market value of roughly $246.27M accounting for 0.72% of the overall portfolio. To date, the estimated cost basis is nearly $82.22 for "buy" trades and estimated average "sell" price is $94.56. Pzena Investment Management first purchased MDT in 2016 Q4, initially acquiring 4,287 shares. Richard Pzena later completely sold out the position and invested in Medtronic PLC again in 2023 Q1. Since the initial investment in Medtronic PLC (MDT), Pzena Investment Management has made 16 more transactions.
When did Richard Pzena buy Medtronic PLC (MDT)?
Richard Pzena first invested in Medtronic PLC (MDT) in 2016 Q4 at the reported quarter-end price of $71.15 per share.
What's the cost basis of Pzena Investment Management's MDT stake?
The estimated cost basis for Medtronic PLC (MDT) stake is around $82.22 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $82.22
- Weighted AVG sell price:
- $94.56
Richard Pzena's historical trades in Medtronic PLC
17 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.72%
|
3,147,999
|
$78.23
|
$246,267,980
|
-0.29% (-9,016)
|
-0%
|
|
2026 Q1
|
0.89%
|
3,157,015
|
$86.65
|
$273,555,338
|
-1.92% (-61,837)
|
-0.02%
|
|
2025 Q4
|
0.93%
|
3,218,852
|
$96.06
|
$309,202,963
|
-45.70% (-2,709,234)
|
-0.84%
|
|
2025 Q3
|
1.82%
|
5,928,086
|
$95.24
|
$564,590,886
|
-33.06% (-2,927,205)
|
-0.91%
|
|
2025 Q2
|
2.51%
|
8,855,291
|
$87.17
|
$771,915,739
|
+5.59% (+469,069)
|
+0.13%
|
|
2025 Q1
|
2.63%
|
8,386,222
|
$89.86
|
$753,585,918
|
+2.08% (+171,205)
|
+0.05%
|
|
2024 Q4
|
2.23%
|
8,215,017
|
$79.88
|
$656,215,530
|
-4.29% (-367,976)
|
-0.09%
|
|
2024 Q3
|
2.49%
|
8,582,993
|
$90.03
|
$772,726,839
|
+3.32% (+275,870)
|
+0.08%
|
|
2024 Q2
|
2.30%
|
8,307,123
|
$78.71
|
$653,853,624
|
+8.32% (+637,931)
|
+0.18%
|
|
2024 Q1
|
2.29%
|
7,669,192
|
$87.15
|
$668,370,086
|
+2.25% (+168,630)
|
+0.05%
|
|
2023 Q4
|
2.32%
|
$82.38
|
+30.89% (+1,769,985)
|
|||
|
2023 Q3
|
1.93%
|
$78.36
|
+112.78% (+3,037,394)
|
|||
|
2023 Q2
|
1.01%
|
$88.10
|
+129.51% (+1,519,728)
|
|||
|
2023 Q1
|
0.41%
|
$80.62
|
new
|
|||
|
2017 Q2
|
0.00%
|
$80.48
|
-100% (-4,560)
|
|||
|
2017 Q1
|
0.00%
|
$80.48
|
+6.37% (+273)
|
|||
|
2016 Q4
|
0.00%
|
$71.15
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.